Literature DB >> 22346333

Vilazodone HCl (Viibryd): A Serotonin Partial Agonist and Reuptake Inhibitor For the Treatment of Major Depressive Disorder.

Martin Paspe Cruz.   

Abstract

Entities:  

Year:  2012        PMID： 22346333      PMCID： PMC3278186     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


× No keyword cloud information.
  5 in total

1.  Norepinephrine and selective norepinephrine reuptake inhibitors in depression and mood disorders: their pivotal roles.

Authors:  P Blier
Journal:  J Psychiatry Neurosci       Date:  2001       Impact factor: 6.186

2.  Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication.

Authors:  Ronald C Kessler; Wai Tat Chiu; Olga Demler; Kathleen R Merikangas; Ellen E Walters
Journal:  Arch Gen Psychiatry       Date:  2005-06

Review 3.  Serotonin: and what about its side effects?

Authors:  E Richelson
Journal:  Depress Anxiety       Date:  1998       Impact factor: 6.505

Review 4.  Partial response and nonresponse to antidepressant therapy: current approaches and treatment options.

Authors:  Robert M A Hirschfeld; Stuart A Montgomery; Eugenio Aguglia; Mario Amore; Pedro L Delgado; Markus Gastpar; Christopher Hawley; Siegfried Kasper; Michael Linden; Juan Massana; Julien Mendlewicz; Hans-Jürgen Möller; Charles B Nemeroff; Jerónimo Saiz; Pedro Such; Riccardo Torta; Marcio Versiani
Journal:  J Clin Psychiatry       Date:  2002-09       Impact factor: 4.384

5.  Duloxetine in the treatment of major depressive disorder.

Authors:  David J Goldstein
Journal:  Neuropsychiatr Dis Treat       Date:  2007-04       Impact factor: 2.570
  5 in total
  10 in total

1.  Synthesis and evaluation of the structural elements in alkylated tetrahydroisoquinolines for binding to CNS receptors.

Authors:  Edward Ofori; Xue Y Zhu; Jagan R Etukala; Barbara A Bricker; Seth Y Ablordeppey
Journal:  Bioorg Med Chem       Date:  2016-09-10       Impact factor: 3.641

Review 2.  Vilazodone for Major Depression in Adults: Pharmacological Profile and an Updated Review for Clinical Practice.

Authors:  Mohit Chauhan; Rebecca Parry; William V Bobo
Journal:  Neuropsychiatr Dis Treat       Date:  2022-06-14       Impact factor: 2.989

Review 3.  Vilazodone for the treatment of major depressive disorder: an evidence-based review of its place in therapy.

Authors:  David J Hellerstein; Joseph Flaxer
Journal:  Core Evid       Date:  2015-04-20

4.  A 12-week Comparative Prospective Open-label Randomized Controlled Study in Depression Patients Treated with Vilazodone and Escitalopram in a Tertiary Care Hospital in North India.

Authors:  Manish Bathla; Shazia Anjum; Manpreet Singh; Saminder Panchal; Gurvinder Pal Singh
Journal:  Indian J Psychol Med       Date:  2018 Jan-Feb

5.  Serotonergic system antagonists target breast tumor initiating cells and synergize with chemotherapy to shrink human breast tumor xenografts.

Authors:  William D Gwynne; Robin M Hallett; Adele Girgis-Gabardo; Bojana Bojovic; Anna Dvorkin-Gheva; Craig Aarts; Kay Dias; Anita Bane; John A Hassell
Journal:  Oncotarget       Date:  2017-05-09

Review 6.  Piperazine based antimicrobial polymers: a review.

Authors:  Manohara Dhulappa Jalageri; Akshatha Nagaraja; Yashoda Malgar Puttaiahgowda
Journal:  RSC Adv       Date:  2021-04-23       Impact factor: 3.361

Review 7.  A systematic review of pharmacologic treatment efficacy for depression in older patients with cancer.

Authors:  Erik E Rabin; Miri Kim; Andreas Mozny; Krislyn Cardoza; April C Bell; Lijie Zhai; Prashant Bommi; Kristen L Lauing; Amanda L King; Terri S Armstrong; Theresa L Walunas; Deyu Fang; Ishan Roy; John D Peipert; Erica Sieg; Xinlei Mi; Christina Amidei; Rimas V Lukas; Derek A Wainwright
Journal:  Brain Behav Immun Health       Date:  2022-03-23

8.  Antidepressant-like activity of YL-0919: a novel combined selective serotonin reuptake inhibitor and 5-HT1A receptor agonist.

Authors:  Hong-xia Chen; Zeng-liang Jin; Li-ming Zhang; Rui Xue; Xiao-dan Xu; Nan Zhao; Zhi-kun Qiu; Xian-wang Wang; You-zhi Zhang; Ri-fang Yang; Yun-feng Li
Journal:  PLoS One       Date:  2013-12-18       Impact factor: 3.240

9.  Identification of the Antidepressant Vilazodone as an Inhibitor of Inositol Polyphosphate Multikinase by Structure-Based Drug Repositioning.

Authors:  Boah Lee; Seung Ju Park; Seulgi Lee; Seung Eun Park; Eunhye Lee; Ji-Joon Song; Youngjoo Byun; Seyun Kim
Journal:  Mol Cells       Date:  2020-03-31       Impact factor: 5.034

10.  The Multimodal Serotonergic Agent Vilazodone Inhibits L-DOPA-Induced Gene Regulation in Striatal Projection Neurons and Associated Dyskinesia in an Animal Model of Parkinson's Disease.

Authors:  Feras Altwal; Connor Moon; Anthony R West; Heinz Steiner
Journal:  Cells       Date:  2020-10-09       Impact factor: 6.600
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.